Sinopharm Group Co (X2S1) AI Stock Analysis

Sinopharm Group Co

(Frankfurt:X2S1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Nationwide healthcare distribution networkA nationwide distribution network serving institutional and retail healthcare customers gives Sinopharm broad commercial reach and supports recurring product flow across multiple channels. This scale can reinforce customer access and make the core distribution model durable over the next several quarters.

Negative Factors

Recent revenue contractionRecent revenue contraction shows that the company’s earlier growth has not continued consistently. A declining top line can reduce operating leverage, limit investment capacity, and make it harder for Sinopharm to offset cost pressures through higher volume over the next several quarters.

Sinopharm Group Co (X2S1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 6.43B
Dividend Yield: 4.83%
Average Volume (3M): 80
Price to Earnings (P/E): 6.1
Beta (1Y): 0.34
Revenue Growth: -4.46%
EPS Growth: 0.14%
Country: Germany
Employees: 94,910
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Distribution

Sinopharm Group Co Business Overview & Revenue Model

Company Description

Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. The company's diverse operations are structured into four key segments. The Pharma...

Sinopharm Group Co Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:X2S1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MCK	74Outperform	$115.96B	26.50	-194.39%	0.34%	8.84%	48.98%
COR	71Outperform	$63.13B	24.47	106.43%	0.73%	5.09%	38.10%
CAH	68Neutral	$58.00B	34.45	-59.73%	0.82%	14.23%	12.28%
HSIC	55Neutral	$9.46B	24.53	12.37%	―	6.49%	10.41%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
YI	40Underperform	$25.04M	-1.59	23.64%	―	-23.90%	-45.45%

* Healthcare Sector Average

Performance Comparison

DE:X2S1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:X2S1	Sinopharm Group Co., Ltd. Unsponsored ADR Class H	9.00	-1.30	-12.65%
COR	Cencora, Inc.	330.84	-7.51	-2.22%
CAH	Cardinal Health	250.48	62.04	32.92%
HSIC	Henry Schein	84.88	20.24	31.31%
MCK	McKesson Corporation	994.58	177.51	21.72%
YI	111, Inc.	2.85	-1.51	-34.57%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Sinopharm Group Co AI Stock Analysis